Verona Pharma has agreed a new $400 million debt facility ... its therapy for chronic obstructive pulmonary disease (COPD). The Anglo-US company has already tapped $50 million of the funding ...
Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...
Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster. The first-in-class dual ...
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...
Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...
Verona Pharma is a clinical stage ... the FDA for maintenance treatment of chronic obstructive pulmonary disease (COPD) on June 26. Back in May 2022, prior to this approval and when Caligan ...
A pivotal phase III trial of Ensifentrine for the maintenance treatment of COPD in China is ongoing. This study is being conducted by Verona's partner in Greater China, Nuance Pharma. Results from ...
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback